Company intelligence / Profile preview

FerroKin BioSciences

San Carlos, California, United States

Ownership: Private
Employees: ~7
Development stage: Other

Overview

FBS0701 completed four Phase I clinical trials and was in Phase II dose-ranging studies in adults and children. Initial data from adult Phase II studies presented at the American Society of Hematology demonstrated the drug's potential as an effective iron chelator with a favorable safety profile, including confidence in ability to control liver iron concentration and favorable renal and gastrointestinal adverse event profiles.[6]

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Shire (acquirer)

Beyond the preview

Go deeper on FerroKin BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FerroKin BioSciences.

Explore the full profile